Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - November 25, 2002
Florida has the second largest number of reported persons living with HIV/AIDS in the United States, and Medicaid is the single largest payer for this patient population.
In addition to statewide Medicaid coverage, Medicare and many private payers, including but not limited to BlueCross BlueShield, AEtna US Healthcare, United HealthCare and Humana, provide reimbursement and benefit coverage for ViroLogic's HIV drug resistance assays. Several key states and the District of Columbia also provide funding for Ryan White Title programs, including those in Florida, California, New York, Michigan, Texas, Alabama, Georgia, South Carolina, North Carolina, Missouri, Pennsylvania, Kansas and Virginia.
"We are pleased that now most of our key markets have established favorable Medicaid reimbursement policies, and the HIV provider network has access to ViroLogic's technologies. Our sales team in Florida is primed and ready to capitalize on this opportunity," said Tien Bui, ViroLogic's Vice President of Sales and Marketing. "I am confident we can continue to build on the strong leadership foundation we have created to drive increasing utilization of resistance testing as a management tool for HIV providers and their patients to facilitate optimal care."
Questions about HIV drug resistance testing and reimbursement can be directed to ViroLogic's reimbursement hotline at 1-87-PHENOAID (1-877-436-6243), or to the websites http://www.virologic.com and http://www.phenosense.com.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company's products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines targeted at emerging drug-resistant viruses.
Certain statements in this press release are forward-looking, including statements relating to use and acceptance of the Company's testing products.
These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that ViroLogic may not realize expected growth in its patient testing business, risks related to the timing of pharmaceutical company clinical trials, the risk that ViroLogic may not realize anticipated benefits from its cost-cutting measures, including expected reductions in burn rate, the risk that the equity investments do not close as expected, whether ViroLogic's products will achieve market acceptance, whether the Company will be successful in increasing revenue or reducing expenses, whether it is able to build brand loyalty and expand revenues, whether it will be able to raise sufficient capital and other risks and uncertainties detailed from time to time in the Company's reports to the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2001.
SOURCE ViroLogic, Inc.
Web Site: http://www.virologic.com
021125
PR021139
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .